MedPath

Effect of Bifidobacterium on Irritable Bowel Syndrome

Not Applicable
Conditions
Irritable Bowel Syndrome
Interventions
Registration Number
NCT00737841
Lead Sponsor
Tohoku University
Brief Summary

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients.

Detailed Description

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients. IBS patients will be enrolled via advertisement. Any IBS subtypes will not be rejected. They will take either 1.0 g of Bifidobacterium breve 3 times a day or same amount of placebo for 8 weeks. IBS symptoms and allied markers will be checked before, during, and after the administration.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Diagnosis of IBS with Rome II definition
Exclusion Criteria
  • Diagnosis of serious diseases (both physically and mentally)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BPlaceboPlacebo
ABifidobacterium breveBifidobacterium breve
Primary Outcome Measures
NameTimeMethod
Adequate relief and SIBSQ2, 0, 2, 4, 8 weeks during treatment and 4 weeks after treatment
Secondary Outcome Measures
NameTimeMethod
Psychometric test, bowel gas, blood, and feces.2, 0, 2, 4, 8 weeks during treatment and 4 weeks after treatment

Trial Locations

Locations (1)

Tohoku University Graduate School of Medicine

🇯🇵

Sendai, Miyagi, Japan

© Copyright 2025. All Rights Reserved by MedPath